Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Trastuzumab + Tucatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 47||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Tucatinib||Tukysa||ONT-380|ARRY-380|irbinitinib||HER2 Inhibitor 25||Tukysa (tucatinib) selectivity inhibits ERBB2 (HER2), resulting in decreased proliferation and increased apoptosis in ERBB2 (HER2) expressing tumor cells (PMID: 28053022). Tukysa (tucatinib) in combination with Herceptin (trastuzumab) and Xeloda (capecitabine) is FDA approved for use in patients with advanced unresectable or metastatic ERBB2 (HER2)-positive breast cancer, including patients with brain metastasis, who have received prior anti-HER2 therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 positive||Her2-receptor positive breast cancer||predicted - sensitive||Trastuzumab + Tucatinib||Phase Ib/II||Actionable||In a Phase Ib clinical trial, the combination of Tukysa (tucatinib) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02025192||Phase I||Capecitabine + Trastuzumab + Tucatinib Trastuzumab + Tucatinib Capecitabine + Tucatinib||A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer||Completed|
|NCT01921335||Phase I||Trastuzumab + Tucatinib||ARRY-380 + Trastuzuamab for Breast w/ Brain Mets||Active, not recruiting|
|NCT03043313||Phase II||Trastuzumab + Tucatinib Tucatinib||Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer||Recruiting|